PetVivo (PETV) 10-K 24 Jun 22 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Mar. 31, 2022	Jun. 28, 2022	Sep. 30, 2021
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--03-31
Entity File Number	000-55167
Entity Registrant Name	PetVivo Holdings, Inc.
Entity Central Index Key	0001512922
Entity Tax Identification Number	99-0363559
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5251 Edina Industrial Blvd
Entity Address, City or Town	Edina
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55439
City Area Code	(952)
Local Phone Number	405-6216
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 16,361,168
Entity Common Stock, Shares Outstanding		9,988,361
Documents Incorporated by Reference [Text Block]	Documents incorporated by reference. There are no annual reports to security holders, proxy information statements, or any prospectus filed pursuant to Rule 424 of the Securities Act of 1933 incorporated herein by reference.
ICFR Auditor Attestation Flag	false
Auditor Firm ID	5036
Auditor Name	Assurance Dimensions
Auditor Location	Margate, Florida
Common Stock [Member]
Title of 12(b) Security	Common Stock
Trading Symbol	PETV
Security Exchange Name	NASDAQ
Warrants [Member]
Title of 12(b) Security	Warrants
Trading Symbol	PETVW
Security Exchange Name	NASDAQ

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Mar. 31, 2021
Current Assets
Cash and cash equivalents	$ 6,106,827	$ 23,578
Accounts receivable	2,596
Inventory, net	98,313
Prepaid expenses and other assets	547,664	123,575
Total Current Assets	6,755,400	147,153
Property and Equipment, net	311,549	214,038
Other Assets:
Deferred offering costs		280,163
Operating lease right-of-use asset	299,101	157,760
Patents and trademarks, net	48,452	27,932
Security deposits	12,830	8,201
Total Other Assets	360,383	474,056
Total Assets	7,427,332	835,247
Current Liabilities
Accounts payable	323,384	408,873
Accrued expenses	784,375	554,012
Convertible notes and accrued interest		235,671
Accrued expenses – related parties		36,808
Operating lease liability – current portion	59,178	26,582
PPP Loan and accrued interest		39,020
Notes payable and accrued interest - directors		20,000
Notes payable and accrued interest – related party		44,554
Note payable and accrued interest (current portion)	6,549	39,528
Total Current Liabilities	1,173,486	1,405,048
Other Liabilities
Note payable and accrued interest (net of current portion)	27,201
Operating lease liability (net of current portion)	239,923	131,178
Share-settled debt obligation – related party, net of debt discount		196,000
Total Other Liabilities	267,124	327,178
Total Liabilities	1,440,610	1,732,226
Stockholders’ Equity (Deficit):
Preferred stock, par value $0.001, 20,000,000 shares authorized, 0 and 0 shares issued and outstanding at March 31, 2022 and March 31, 2021
Common stock, par value $0.001, 250,000,000 shares authorized, 9,988,361 and 6,799,113 shares issued and outstanding at March 31, 2022 and March 31, 2021, respectively	9,988	6,799
Additional Paid-In Capital	69,103,155	57,207,648
Accumulated Deficit	(63,126,421)	(58,111,426)
Total Stockholders’ Equity (Deficit)	5,986,722	(896,979)
Total Liabilities and Stockholders’ Equity (Deficit)	$ 7,427,332	$ 835,247

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Mar. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	9,988,361	6,799,113
Common stock, shares outstanding	9,988,361	6,799,113

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenues	$ 115,586	$ 12,578
Cost of Sales	201,154	10,695
Gross Profit (Loss)	(85,568)	1,883
Operating Expenses:
Sales and Marketing	1,347,585	94,977
Research and Development	474,881	98,230
General and Administrative	3,148,494	1,767,664
Total Operating Expenses	4,970,960	1,960,871
Operating Loss	(5,056,528)	(1,958,988)
Other Income (Expense)
Gain on Debt Extinguishment		366,903
Forgiveness of PPP loan and accrued interest	31,680
Derivative Expense		(1,702,100)
Interest Income (Expense)	9,853	(228,595)
Total Other Income (Expense)	41,533	(1,563,792)
Net Loss before taxes	(5,014,995)	(3,522,780)
Income Tax Provision
Net Loss	$ (5,014,995)	$ (3,522,780)
Net Loss Per Share:
Basic and Diluted	$ (0.57)	$ (0.57)
Weighted Average Common Shares Outstanding:
Basic and Diluted	8,760,877	6,198,717

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity(deficit) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Common Stock to Be Issued [Member]	Total
Beginning balance, value at Mar. 31, 2020	$ 5,728	$ 53,494,747	$ (54,588,645)	$ 52,000	$ (1,036,170)
Beginning balance, shares at Mar. 31, 2020	5,727,965
Adjustment for 1-for-4 reverse stock split
Adjustment for 1-for-4 reverse stock split, shares	724
Common stock sold	$ 246	368,254		(52,000)	316,500
Common stock sold, shares	246,071
Cash paid to exercise warrants	$ 206	455,291			455,497
Cash paid to exercise warrants, shares	205,946
Cashless warrant exercises	$ 108	(108)
Cashless warrant exercises, shares	107,705
Stock issued for services	$ 205	541,003			541,208
Stock issued for services, shares	204,752
Stock-based compensation		452,674			452,674
Stock issued for debt conversion	$ 306	1,804,286			1,804,592
Stock issued for debt conversion, shares	305,950
Warrants issued with convertible debt		91,500			91,500
Net loss			(3,522,780)		(3,522,780)
Ending balance, value at Mar. 31, 2021	$ 6,799	57,207,648	(58,111,426)		(896,979)
Ending balance, shares at Mar. 31, 2021	6,799,113
Common stock sold	$ 2,560	5,309,069			5,311,629
Common stock sold, shares	2,560,014
Warrants sold		4,889,252			4,889,252
Cash paid to exercise warrants	$ 6	42,025			42,031
Cash paid to exercise warrants, shares	6,094
Cashless warrant exercises	$ 200	(200)
Cashless warrant exercises, shares	200,044
Stock issued for services	$ 126	524,104			524,230
Stock issued for services, shares	126,194
Stock-based compensation		702,896			702,896
Stock issued for debt conversion	$ 80	232,578			232,658
Stock issued for debt conversion, shares	80,522
Vesting of restricted stock units	$ 173	(173)
Vesting of restricted stock units, shares	172,824
Stock and warrants granted for debt conversion	$ 44	195,956			196,000
Stock and warrants granted for debt conversion, shares	43,556
Net loss			(5,014,995)		(5,014,995)
Ending balance, value at Mar. 31, 2022	$ 9,988	$ 69,103,155	$ (63,126,421)		$ 5,986,722
Ending balance, shares at Mar. 31, 2022	9,988,361

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders' Equity(deficit) (Parenthetical)	1 Months Ended	12 Months Ended
	Oct. 31, 2020	Mar. 31, 2022
Statement of Stockholders' Equity [Abstract]
Reverse stock split, description	the Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was effectuated on December 29, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 to 250,000,000; all share and per share data has been retroactively adjusted for this reverse split for all periods presented	1-for-4 reverse stock split

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss For The Period	$ (5,014,995)	$ (3,522,780)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Derivative expense		1,702,100
Stock-based compensation	702,896	452,674
Stock issued for services	84,130	541,208
Investor relations services paid in stock	220,050
Depreciation and amortization	65,153	86,712
Amortization of debt discount		174,595
Forgiveness of PPP loan and accrued interest	(31,680)
(Gain) on debt extinguishment		(366,903)
Changes in Operating Assets and Liabilities
(Increase) decrease in prepaid expenses and other assets	(208,668)	9,948
Increase in accounts receivable	(2,596)	1,000
Increase in inventories	(98,313)
Interest accrued on convertible notes payable	(3,013)	(1,310)
Interest accrued on notes payable - related party	4,013
Interest accrued on notes payable - directors		382
Interest accrued on PPP Loan		355
Increase (decrease) in accounts payable and accrued expense	144,874	174,652
Increase (decrease) in accrued expenses - related party	(36,808)	(19,799)
Net Cash Used In Operating Activities	(4,174,957)	(767,166)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of equipment	(154,030)	(140,685)
Disbursements for patents and trademarks	(29,154)	(19,479)
Net Cash Used in Investing Activities	(183,184)	(160,164)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from stock and warrants sold	10,200,881	316,500
Proceeds from exercise of warrants	42,031	455,497
Decrease (Increase) in deferred offering costs	280,163	(280,163)
Equity sale proceeds receivable		52,000
Proceeds from PPP loan		38,665
Proceeds from notes payable - directors		45,000
Proceeds from notes payable		35,000
Proceeds from convertible notes		297,500
Repayments of notes payable	(5,778)	(2,972)
Repayments of PPP loan	(7,340)
Repayments of notes payable - related party	(48,267)	(16,701)
Repayments of notes payable - directors	(20,300)
Net Cash Provided by Financing Activities	10,441,390	940,326
Net Increase in Cash and Cash Equivalents	6,083,249	12,996
Cash and Cash Equivalents at Beginning of Year	23,578	10,582
Cash and Cash Equivalents at End of Year	6,106,827	23,578
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Interest	9,642	36,596
SUPPLEMENTAL DISCLOSURE ON NON-CASH FINANCING AND INVESTING ACTIVITIES
Derivative treated as debt discount		352,941
Stock granted for debt conversion	232,658	1,804,592
Warrants issued in debt financing		91,500
Stock granted for share-settled debt obligation conversion	196,000
Stock granted for investor relations services	220,050
Increase to operating lease right of use asset and operating lease liability	167,924
Accounts payable – related party converted to share-settlement debt obligation – related party		196,000
Leasehold improvements included in accounts payable		33,580
Warrants converted		103
Note payable – related party converted into common stock		$ 25,382

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	12 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Organization and Description The Company is in the business of commercializing its proprietary medical devices and biomaterials for the treatment of afflictions and diseases in animals, initially for dogs and horses. The Company’s operations are conducted from its headquarter facilities in Minneapolis, Minnesota. (B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc. through a statutory merger, in which Gel-Del and its wholly-owned subsidiary, Cosmeta, Inc. became wholly-owned subsidiaries of the Company. In October 2020, the Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was effectuated on December 29, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 250,000,000 (C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations, Gel-Del Technologies, Inc. and PetVivo, Inc. All intercompany accounts have been eliminated upon consolidation. (D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include inventory obsolescence, estimated useful lives and potential impairment of property and equipment and intangibles, estimate of fair value of share-based payments and derivative instruments and recorded debt discount, lease assets and liabilities and valuation of deferred tax assets. (E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had no (F) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed federally insured limits. As of March 31, 2022, the Company did have cash balances in excess of the federally insured limits. At March 31, 2021, the Company did not have any cash balances in excess of the federally insured limits. (G) Property & Equipment Property and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after considering their respective estimated residual values) over the assets estimated useful life of ( 3 5 7 (H) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of useful life of 60 (I) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 3,754,484 1.20 6.67 4.95 The Company has 372,668 3.00 9.50 3.85 The Company has 195,000 1.39 1.99 1.56 The Company has 1,081,668 1.20 10.00 2.02 The Company uses the guidance in Accounting Standards Codification 260 (“ASC 260”) to determine if-converted loss per share. ASC 260 states that convertible securities should be considered exercised at the later date of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be anti-dilutive. At March 31, 2021, the Company had $ 230,000 5,671 June 30, 2021 230,000 5,671 81,579 2.89 196,000 (J) Revenue Recognition The Company derives revenue from the sale of pet care products to its veterinarian customers in the Unites States. For performance obligations related to the sale of our pet care products, control transfers to the customer at a point in time. Revenue is recognized upon shipment, which is when control of these products is transferred to our customers and in an amount that reflects the consideration the Company expects to receive for these products. Shipping cost charged to customers are reported as an offset to the respective shipping cost. The Company does not have any significant financing components as payment is received at or shortly after the point of sale. (K) Accounts Receivable Accounts receivable are recorded at management’s assessment of the expected consideration to be received, based on a detailed review of historical pricing adjustments and collections. Management relies on the results of the assessment, which includes payment history of the applicable customer as a primary source of information in estimating the collectability of our accounts receivable. We update our assessment on a quarterly basis, which to date has not resulted in any material adjustments to the valuation of our accounts receivable. We believe the assessment provides reasonable estimates of our accounts receivable valuation, and therefore believe that substantially all accounts receivable are fully collectible. (L) Research and Development The Company expenses research and development costs as incurred. (M) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of accounts receivable, accounts payable, accrued expenses, accrued expenses – related parties, notes payable and accrued interest, and notes payable and accrued interest - related party, notes payable – directors and others. The carrying amount of the Company’s financial instruments approximates their fair value as of March 31, 2022 and 2021, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company had no (N) Stock-Based Compensation - Non-Employees Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of Sub-topic 505-50 of the FASB Accounting Standards Codification (“Sub-topic 505-50”). Pursuant to ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. Pursuant to Paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a share option and similar instrument that the counterparty has the right to exercise expires unexercised. (O) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. As required by ASC Topic 450, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. At the adoption date, the Company applied ASC Topic 740 to all tax positions for which the statute of limitations remained open. As a result of the implementation of ASC Topic 740, the Company did not recognize any change in the liability for unrecognized tax benefits. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses. (P) Inventory Inventories are recorded in accordance with ASC 330, Inventory, and are stated at the lower of cost or net realizable value. We account for inventories using the first in first out (FIFO) methodology. (Q) Recent Accounting Pronouncements The Company has reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) - Accounting for Convertible Instruments and Contracts on an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exceptions. The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early adoption is permitted. The Company is currently evaluating the impact of the adoption of the standard on the consolidated financial statements. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). The new ASU addresses issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact this new guidance will have on its financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable. (R) Reclassifications Certain accounts in the prior year financial statements have been reclassified for comparative purposes to conform with the presentation in the current year financial statements. Accrued expenses is reported separately from accounts payable in the balance sheet since the amounts are material. In addition, the change in deferred offering costs is classified as a financing activity in the statement of cash flows. There was no effect on the change in net assets or net increase in cash and cash equivalents from these reclassifications.

INVENTORY

INVENTORY	12 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
INVENTORY	NOTE 2 – INVENTORY As of March 31, 2022 and March 31, 2021, the Company had inventory of $ 98,313 47,068 47,068 The inventory components are as follows: SCHEDULE OF INVENTORY March 31, 2022 March 31, 2021 Finished Goods $ 11,889 $ 36,973 Work in Process 22,960 - Raw Materials 63,464 8,773 Manufacturing Supplies - 1,322 Inventory, Gross 98,313 47,068 Reserve for Obsolete Inventory - (47,068 ) Total Net $ 98,313 $ - At March 31, 2022, both the inventory cost of $ 47,068 no The Company recognized a benefit to cost of sales of $ 3,289 For the year ended March 31, 2022, the Company reported a negative gross margin on sales as a result of production costs to build inventory levels to support the launch of our product in October 2021.

PREPAID EXPENSES AND DEFERRED O

PREPAID EXPENSES AND DEFERRED OFFERING COSTS	12 Months Ended
	Mar. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND DEFERRED OFFERING COSTS	NOTE 3 – PREPAID EXPENSES AND DEFERRED OFFERING COSTS As of March 31, 2022, the Company had $ 547,664 in prepaid expenses and other assets consisting primarily of $ 220,000 of stock based compensation in investor relations services, $ 148,000 in insurance costs, $ 71,000 in clinical studies, $ 46,000 in tradeshows and $ 45,000 in Nasdaq fees. As of March 31, 2021, the Company had $ 123,575 78,000 9,000 9,000 280,163

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 – PROPERTY AND EQUIPMENT The components of property and equipment were as follows: SCHEDULE OF PROPERTY AND EQUIPMENT March 31, 2022 March 31, 2021 Leasehold improvements $ 216,159 $ 198,015 Production equipment 197,967 128,849 R&D equipment 25,184 25,184 Computer equipment and furniture 76,898 10,130 Total, at cost 516,208 362,178 Accumulated depreciation (204,659 ) (148,140 ) Total Net $ 311,549 $ 214,038 During the year ended March 31, 2022 and 2021, depreciation expense was $ 56,519 36,554

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 5 – INTANGIBLE ASSETS The components of intangible assets, all of which are finite-lived, were as follows: SCHEDULE OF INTANGIBLE ASSETS March 31, 2022 March 31, 2021 Patents $ 3,870,057 $ 3,840,903 Trademarks 26,142 26,142 Total at cost 3,896,199 3,867,045 Accumulated Amortization (3,847,747 ) (3,839,113 ) Total net $ 48,452 $ 27,932 During the year ended March 31, 2022 and 2021, amortization expense was $ 8,634 50,158

ACCRUED EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Mar. 31, 2022
Accrued Expenses
ACCRUED EXPENSES	NOTE 6 – ACCRUED EXPENSES The components of accrued expenses were as follows: SCHEDULE OF COMPONENTS OF ACCRUED EXPENSES March 31, 2022 March 31, 2021 Accrued payroll and related taxes $ 452,137 $ 221,774 Accrued lease termination expense 332,238 332,238 Total $ 784,375 $ 554,012 Pursuant to a lease wherein our subsidiary, Gel-Del Technologies, Inc., was the lessee until and through the lease’s termination in fiscal year 2017-2018, the Company had recorded as of those fiscal years approximately $ 332,000

RELATED PARTY NOTES PAYABLE

RELATED PARTY NOTES PAYABLE	12 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY NOTES PAYABLE	NOTE 7 - RELATED PARTY NOTES PAYABLE At March 31, 2022 and March 31, 2021, the Company is obligated for a related party note payable and accrued interest in the total amount of $ 0 44,554 April 30, 2020 3,100 24 3,500,000 The Company entered into notes payable with four directors in March 2021 which accrue interest at a rate of 6% 0 20,000

NOTES PAYABLE AND CONVERTIBLE N

NOTES PAYABLE AND CONVERTIBLE NOTES	12 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE AND CONVERTIBLE NOTES	NOTE 8 – NOTES PAYABLE AND CONVERTIBLE NOTES In January 2020, the Company entered into a lease amendment for our corporate office facility whereby the lease term was extended through November of 2026 in exchange for a loan of $ 42,500 6% 33,750 39,528 6,549 27,201 On May 1, 2020, the Company received $ 38,665 39,020 1% May 1, 2022 31,680 3,769 738 At March 31, 2021, the Company is obligated for several convertible notes payable in the total amount of $ 235,671 230,000 5,671 10% 2,658 80,522 2.89 The Company entered into a convertible note payable held by RedDiamond Partners, LLC (“RDCN”) on June 15, 2020, whereby the RDCN was convertible on or after January 15, 2021 and before maturity on March 15, 2021 at a rate of $ 1.12 352,941 52,941 15% 12.5% 139,286 91,500 0 352,941 91,500 2,500 52,941 206,000 30,000 75,000 31,500 61,500 52,399 173,174 368,995 352,941 16,054 263,568 1.40 6.56 1,908,100 368,995 181,187 1,729,005 366,903 0 0

SHARE-SETTLED DEBT OBLIGATION _

SHARE-SETTLED DEBT OBLIGATION – RELATED PARTY	12 Months Ended
	Mar. 31, 2022
Share-settled Debt Obligation Related Party
SHARE-SETTLED DEBT OBLIGATION – RELATED PARTY	NOTE 9 – SHARE-SETTLED DEBT OBLIGATION – RELATED PARTY Effective September 1, 2020, the Company entered into two debt settlement agreements with David B. Masters, a director of the Company, pursuant to an Amendment to Promissory Note and a Promissory Note. The Amendment to Promissory Note extends, for up to an additional two years and under the same terms as originally entered into, the original promissory notes which were issued by Gel-Del Technologies, Inc., a wholly owned subsidiary of the Company, to Dr. Masters. Because this Amendment to Promissory Note simply extended the term over which the Company is required to pay back the outstanding balance this change has been treated as a debt modification. The outstanding principal of $ 59,642 6,058 65,700 8% 20% The Amendment to Promissory Note requires monthly payments of $ 3,100 June 30, 2022 The Promissory Note was entered into with an effective date of September 1, 2020 in a principal amount of $ 195,000 David Masters’ release of any claim to the $ 195,000 4,000 195,000 A Settlement and General Release (“ Settlement Agreement On October 15, 2020, the Company entered into a note conversion agreement with David Masters whereby the Company and Dr. Masters both agreed to convert his note payable in the then outstanding balance of $ 193,158 192,500 658 196,000 192,500 3,500 658 3,500 658 196,000 43,556 43,556 43,556 At March 31, 2022 and March 31, 2021, the Company was obligated for principal and accrued interest in the amounts of $- 0 196,000 0 44,554

DERIVATIVE LIABILITY AND EXPENS

DERIVATIVE LIABILITY AND EXPENSE	12 Months Ended
	Mar. 31, 2022
Derivative Liability And Expense
DERIVATIVE LIABILITY AND EXPENSE	NOTE 10 – DERIVATIVE LIABILITY AND EXPENSE The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operation as other income (expense). Upon conversion or exercise of a derivative instruments, the instrument is marked to fair value at the conversion date then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date. The Company used the following assumptions for determining the fair value of the conversion feature in the RDCN referenced in Note 8 to these financial statements, under the binomial pricing model with Monte Carlo simulations at June 15, 2020, September 30, 2020 and October 26, 2020, the issuance, balance sheet, and conversion dates, respectively: SCHEDULE OF DERIVATIVE LIABILITY ASSUMPTIONS June 15, 2020 September 30, 2020 October 26, 2020 Stock price on valuation date $ 1.68 $ 1.60 $ 6.56 Conversion price $ 1.12 $ 1.12 $ 1.12 Days to maturity 273 166 140 Weighted-average volatility* 367 % 327 % 197 % Risk-free rate .18 % .12 % .11 % The initial valuation of $ 526,800 206,000 0 320,800 526,800 937,500 1,908,100 1,702,100 263,568 1.40 366,903 no

ACCRUED EXPENSES _ RELATED PART

ACCRUED EXPENSES – RELATED PARTY	12 Months Ended
	Mar. 31, 2022
Accrued Expenses Related Party
ACCRUED EXPENSES – RELATED PARTY	NOTE 11– ACCRUED EXPENSES – RELATED PARTY At March 31, 2021, the Company was obligated to pay $ 36,808 28,965 7,843 In August 2021, the total amount due to the related party was paid from the proceeds of its Public Offering and there is no

RETIREMENT PLAN

RETIREMENT PLAN	12 Months Ended
	Mar. 31, 2022
Retirement Benefits [Abstract]
RETIREMENT PLAN	NOTE 12– RETIREMENT PLAN In February 2021, the Company established a 401(k)-retirement plan for its employees in which eligible employees can contribute a percentage of their compensation. The Company may also make discretionary contributions. The Company made contributions to the plan of $ 8,000

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 13 – COMMITMENTS AND CONTINGENCIES Lease Obligations The Company entered into an eighty-four month lease for 3,577 2% In January 2020, the Company entered into a lease amendment whereby agreed to extend the lease term through November of 2026 42,500 7,500 2,205 The Company entered into an sixty-three month lease for 2,400 2.5% 2,673 Rent expense for the years ended March 31, 2022 and March 31, 2021 were $ 81,816 56,546 The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of March 31, 2022: SCHEDULE OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY 2023 $ 59,243 2024 60,588 2025 61,964 2026 63,372 2027 55,102 Total 300,270 Less: amount representing interest (1,169 ) Total $ 299,101 In connection with the lease that was added in January 2022, the Company recorded an operating lease right of use asset and corresponding operating lease liability of $ 167,924 the extended lease term to November 2026 and March 2027 0.12% 0.40% 488,701 4.8 0.28% SCHEDULE OF BASE RENT LEASE PAYMENTS Present value of future base rent lease payments $ 299,101 Present value of future base rent lease payments – net $ 299,101 As of March 31, 2022, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES Operating lease right-of-use asset $ 299,101 Total operating lease assets 299,101 Operating lease current liability 59,178 Operating lease other liability 239,923 Total operating lease liabilities $ 299,101 Employment Agreements The Company has employment agreements with its executive officers. As of March 31, 2022, these agreements contain severance benefits ranging from one month to six months if terminated without cause. As of March 31, 2021, the employment agreements to executive officers did not contain severance benefits if terminated without cause. Legal Proceedings The Company has received correspondence from an attorney representing Dr. David Masters, our former Chief Technology Officer and former director, alleging that the Company, among other items, breached its settlement and consulting agreement with him and owes him additional monies pursuant to these agreements. His attorney also alleges that the Company promised to enter into a new employment agreement with him and failed to fulfill that promise. The Company believes that Dr. Master’s claims are without merit and has retained legal counsel. The Company does not believe that this matter will have a material impact on its financial position or results of operations. Purchase Commitment We issued purchase orders in the fiscal year ended March 31, 2022 totaling $ 250,000

GOING CONCERN

GOING CONCERN	12 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 14 - GOING CONCERN The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The financial statements have been prepared assuming that we will continue as a going concern, which contemplates that we will realize our assets and satisfy our liabilities and commitments in the ordinary course of business. In August 2021, we raised net proceeds of approximately $ 9,781,000 2,500,000 4.50 5,581,914 The Company expects to incur losses in the future as its commercially launches its first product. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months after the date of issuance of these consolidated financial statements. Management intends to raise additional funds by selling securities in public or private offerings. Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern. While the Company believes in its viability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and raise additional funds. COVID-19 has had an impact on the global economy, which directly or indirectly may have an impact on our ability to continue as a going concern.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Mar. 31, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 15 – STOCKHOLDERS’ EQUITY Equity Incentive Plan On July 10, 2020, our Board of Directors unanimously approved the PetVivo Holdings, Inc “2020 Equity Incentive Plan” (the “2020 Plan”), subject to approval by our stockholders at a Meeting of Stockholders held on September 22, 2020, when it was approved by our stockholders and became effective. The number of shares of our common stock authorized under the 2020 Plan is 1,000,000 July 10, 2030 233,923 Employees, consultants and advisors of the Company (or any subsidiary), and non-employee directors of the Company will be eligible to receive awards under the 2020 Plan. In the case of consultants and advisors, however, their services cannot be in connection with the offer and sale of securities in a capital-raising transaction nor directly or indirectly promote or maintain a market for PetVivo securities. The 2020 Plan is administered by the Compensation Committee of our Board of Directors (the “Committee”), which has full power and authority to determine when and to whom awards will be granted, and the type, amount, form of payment, any deferral payment, and other terms and conditions of each award. Subject to provisions of the 2020 Plan, the Committee may amend or waive the terms and conditions, or accelerate the exercisability, of an outstanding award. The Committee has the authority to interpret and establish rules and regulations for the administration of the 2020 Plan. In addition, the Board of Directors may also exercise the powers of the Committee. The aggregate number of shares of PetVivo common stock available and reserved to be issued under the 2020 Plan is 1,000,000 ● the maximum aggregate number of shares of Common Stock granted as an Award to any Non-Employee Director in any one Plan Year will be 25,000 Awards can be granted for no cash consideration or for any cash and other consideration as determined by the Committee. Awards may provide that upon the grant or exercise thereof, the holder will receive cash, shares of PetVivo common stock, other securities or property, or any combination of these in a single payment, installments or on a deferred basis. The exercise price per share of any stock option and the grant price of any stock appreciation right may not be less than the fair market value of PetVivo common stock on the date of grant. The term of any award cannot be longer than ten years from the date of grant. Awards will be adjusted in the event of a stock dividend or other distribution, recapitalization, forward or reverse stock split, reorganization, merger or other business combination, or similar corporate transaction, in order to prevent dilution or enlargement of the benefits or potential benefits provided under the 2020 Plan. The 2020 Plan permits the following types of awards: stock options, stock appreciation rights, restricted stock awards, restricted stock units, deferred stock units, performance awards, non-employee director awards, other stock-based awards, and dividend equivalents. Units – Public Offering On August 13, 2021, the Company sold an aggregate of 2,500,000 4.50 5.625 43,556 196,000 4.50 The Company received gross proceeds of $ 11,253,850 8% 1,473,067 4,891,531 4,889,252 In addition, pursuant to the Underwriting Agreement, the Company granted ThinkEquity a 45-day option to purchase up to 375,000 additional shares of common stock, and/or 375,000 additional warrants, to cover over-allotments in connection with the Offering, which ThinkEquity partially exercised to purchase 375,000 warrants on the closing date. Pursuant to the Underwriting Agreement, we issued warrants (the “Underwriter’s Warrants”) to ThinkEquity to purchase 125,000 5% 5.625 five years Common Stock For the year ended March 31, 2022, the Company issued 3,189,248 i) 80,522 230,000 2,658 2.89 ii) 4,500 4.44 40,000 iii) 36,915 42,188 1.33 iv) 79,767 90,500 1.40 v) 49,014 343,098 7.00 vi) 43,324 56,250 2.22 vii) 11,000 77,000 7.00 viii) 2,500,000 4.50 ix) 43,556 196,000 4.50 x) 40,038 48,786 1.40 xi) 1,594 1.27 2,031 xii) 42,000 210,000 xiii) 25,585 69,080 xiv) 500 2,000 xv) 300 xvi) 10,000 xvii) 7,500 20,100 xviii) 42,000 210,000 xix) 8,609 13,050 xx) 162,524 For the year ended March 31, 2021, the Company issued 1,070,424 i) 30,000 32,453 ii) 20,000 34,709 20,000 34,709 17,291 52,000 iii) 12,500 22,000 10,000 17,600 2,500 4,400 iv) 15,257 12,053 25,000 15,257 1.20 v) 226,071 316,500 vi) 162,252 486,755 a. 33,619 b. 26,217 c. 22,993 d. 10,789 e. 10,711 f. 10,627 g. 10,550 h. 9,302 i. 9,300 j. 9,209 k. 8,935 vii) 25,003 25,383 25,382 25,000 382 1.02 viii) 263,568 368,995 1,729,005 ix) 32,347 42,188 1.33 x) 202,499 2.22 449,993 xi) 793 6,750 4.44 xii) 17,379 50,000 205 2.89 xiii) 38,516 42,188 1.33 xiv) 15,629 17,187 1.33 xv) 5,163 9,000 4.44 xvi) 3,447 1.60 5,504 On October 31, 2019, the Company’s Board of Directors also approved a compensation plan for John Lai that included his retention of 150,000 John Lai (CEO & Director), Randall Meyer (Director), and John Dolan (Secretary & Director) are all related parties, and the reduction of $ 375,936 80,029 81,738 Time-Based Restricted Stock Units We have granted time-based restricted stock units to certain participants under the 2020 Plan that are stock-settled with common shares. Time-based restricted stock units granted under the 2020 Plan vest over three years. Stock-based compensation expense included in the Consolidated Statements of Operations for time-based restricted stock units was $ 606,014 1,505,000 2.3 Our time-based restricted stock unit activity for the year ended March 31, 2022 was as follows: SCHEDULE OF TIME BASED RESTRICTED STOCK UNITS Units Weighted Average Grant Date Fair Value Per Unit Aggregate Intrinsic Value (1) Balance at March 31, 2021 - - - Granted 549,565 $ 3.86 - Expired (4,073 ) $ 2.70 Vested (172,874 ) 3.44 Balance at March 31, 2022 372,668 $ 4.07 $ 760,243 (1) The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of this period. Stock Options Stock options issued to employees typically vest over three years seven years 3,595 No 299,000 6.9 The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model. Annually, we make predictive assumptions regarding future stock price volatility, dividend yield, expected term and forfeiture rate. The dividend yield assumption is based on expected annual dividend yield on a grant date. To date, no dividend on common stock has been paid by us. Expected volatility for grants is based on our average historical volatility over a similar period as the expected term assumption used for our options as the expected volatility. The risk-free interest rate is based on yields of U.S. Treasury securities with maturities similar to the expected term of the options for each option group. We use the “simplified method” to determine the expected term of the stock option grants. We utilize this method because we do not have sufficient public company exercise date in which to make a reasonable estimate. The following table sets forth the estimated fair values of our stock options granted: SCHEDULE OF ESTIMATED FAIR VALUES ASSUMPTIONS Year Ended March 31, 2022 Expected term 7 years Expected volatility 205.0% 210.5 % Risk-free interest rate 1.47% 2.14 % Expected dividend yield 0 % Fair value on the date of grant $ 1.39 1.99 Our stock option activity for the year ended March 31, 2022 was as follows: SCHEDULE OF STOCK OPTION ACTIVITY Options Weighted- Average Exercise Price Per Share (1) Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value (2) Balance at March 31, 2021 - - - - Granted 195,000 $ 1.56 - Balance at March 31, 2022 195,000 $ 1.56 6.9 $ 100,200 (1) The exercise price of each option granted during the period shown above was equal to the market price of the underlying stock on the date of grant. (2) The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of this period. There were no The following summarizes additional information about our stock options: SCHEDULE OF ADDITIONAL INFORMATION ABOUT STOCK OPTIONS Year Ended March 31, 2022 Number of: Non-vested options, beginning of year - Non -vested options, end of year 195,000 Vested options, end of year - Year Ended March 31, 2022 Weighted-average grant date fair value of: Non-vested options, beginning of year - Non-vested options, end of year $ 1.56 Vested options, end of year - Forfeited options, during the year - Warrants During the year ended March 31, 2022, the Company issued warrants to purchase an aggregate of 3,043,556 ● warrants to purchase 2,500,000 4,805,528 5.625 ● warrants to purchase 43,556 196,000 83,724 5.625 ● warrants to purchase 500,000 5.625 These warrants’ values were arrived at by using the Black-Scholes valuation model with the following assumptions: i) an expected volatility of the Company’s shares on the date of the grants of approximately 315 ii) risk-free rate identical to the U.S. Treasury 5 0.82 During the year ended March 31, 2021, the Company issued warrants to purchase a total of 240,632 i) warrants issued for 10,000 17,291 4.00 3 years ii) warrants issued for 38,846 57,707 1.40 1.60 1.52 iii) warrants issued with debt for 158,036 265,500 91,500 1.40 iv) warrants for 3,750 6,600 5 years 1.20 v) warrants for 30,000 96,000 5 years 1.40 These warrants’ values were arrived at by using the Black-Scholes valuation model with the following assumptions: i) an expected volatility of the Company’s shares on the date of the grants of between approximately 350 433 ii) ii) risk-free rates identical to the U.S. Treasury 3 5 0.29 1.16% A summary of warrant activity for the year ending March 31, 2020 and nine-month period ending December 31, 2021 is as follows: SCHEDULE OF WARRANT ACTIVITY Number of Weighted-Average Warrants Weighted- Outstanding, March 31, 2020 1,234,295 $ 2.12 1,027,092 $ 2.13 Issued in conjunction with convertible debt 158,036 1.40 Sold for Cash 10,000 4.00 Issued and granted 72,596 1.52 Exercised for cash (205,946 ) (2.21 ) Cashless warrant exercises (142,313 ) (1.64 ) Expired (45,000 ) (3.78 ) Outstanding, March 31, 2021 1,081,668 2.02 881,982 2.00 Issued and granted 3,043,556 5.63 Exercised for cash (6,094 ) (6.90 ) Cashless warrant exercises (237,724 ) (1.58 ) Expired (15,922 ) (5.27 ) Cancelled (108,000 ) (1.79 ) Outstanding, March 31, 2022 3,757,484 $ 4.95 3,693,734 $ 5.00 At March 31, 2022, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: SCHEDULE OF RANGE OF WARRANT PRICES Warrants Outstanding Warrants Exercisable Range of Warrant Exercise Price Number of Warrants Weighted- Average Exercise Price Weighted-Average Remaining Contractual Life (Years) Number of Warrants Weighted- Average Exercise Price $ 1.20 2.00 418,237 $ 1.35 3.93 418,237 $ 1.35 2.01 4.00 207,938 2.48 2.34 134,813 2.59 4.01 6.67 3,131,309 5.60 4.26 3,131,309 5.60 Total 3,757,484 $ 4.95 4.12 3,693,734 $ 5.00 For the year ended March 31, 2022 and 2021, the total stock based compensation on all instruments was $ 702,896 452,674 31,000

INCOME TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 16 – INCOME TAXES The following table presents the net deferred tax assets as of March 31, 2022 and 2021: SCHEDULE OF DEFERRED TAX ASSETS 2022 2021 Net operating loss carryforwards $ 5,091,000 $ 4,924,000 Stock compensation 512,000 307,000 Other 96,000 44,000 Total deferred tax assets 5,699,000 5,275,000 Valuation allowance (5,699,000 ) (5,275,000 ) Net deferred tax assets $ — $ — Current income taxes are based upon the year’s income taxable for federal and state tax reporting purposes. Deferred income taxes (benefits) are provided for certain income and expenses, which are recognized in different periods for tax and financial reporting purposes. Deferred tax assets and liabilities are computed for differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the period in which the differences are expected to affect taxable income. The Company’s deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers would be limited under the Internal Revenue Code should a significant change in ownership occur within a three-year period. At March 31, 2022 and 2021, respectively, the Company had net operating loss carryforwards of approximately $ 17,700,000 17,100,000 5,091,000 4,924,000 424,000 441,000 The net operating loss carryforwards, if not utilized, generally expire twenty years from the date the loss was incurred, beginning in 2022, and losses incurred after 2019 are carried forward indefinitely and subject to annual limitations for federal and Minnesota purposes. Of the approximately $ 17,700,000 7,000,000 7,000,000 Income tax expense (benefits) to the statutory rate of 21% for the years ended March 31, 2022 and 2021 is as follows: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION 2022 2021 Tax benefits at statutory rate 21.0 % 21.0 % State income tax benefit, net of federal 7.7 % 7.7 % Tax rate adjustment to deferred tax assets - 3.2 % Gross effective rate 28.7 % 31.9 % Valuation allowance (28.7 %) (31.9 %) Net effective rate - - The Company’s continuing practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of March 31, 2022 and 2021, the Company had no The Company is subject to taxation in the U.S. and Minnesota. Our tax years for 2019 and forward are subject to examination by tax authorities. The Company is not currently under examination by any tax authority. Management has evaluated tax positions in accordance with FASB ASC 740, and has not identified any tax positions, other than those discussed above, that require disclosure.

SUBSEQUENT EVENT

SUBSEQUENT EVENT	12 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENT	NOTE 17 – SUBSEQUENT EVENT On June 17, 2022, the Company entered into an exclusive distribution agreement (“agreement”) with MWI Veterinary Supply Company. The term of the agreement is for two years and can be extended for a third year if certain milestones are achieved.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Policies)	12 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description	(A) Organization and Description The Company is in the business of commercializing its proprietary medical devices and biomaterials for the treatment of afflictions and diseases in animals, initially for dogs and horses. The Company’s operations are conducted from its headquarter facilities in Minneapolis, Minnesota.
Basis of Presentation	(B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc. through a statutory merger, in which Gel-Del and its wholly-owned subsidiary, Cosmeta, Inc. became wholly-owned subsidiaries of the Company. In October 2020, the Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was effectuated on December 29, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 250,000,000
Principles of Consolidation	(C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations, Gel-Del Technologies, Inc. and PetVivo, Inc. All intercompany accounts have been eliminated upon consolidation.
Use of Estimates	(D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include inventory obsolescence, estimated useful lives and potential impairment of property and equipment and intangibles, estimate of fair value of share-based payments and derivative instruments and recorded debt discount, lease assets and liabilities and valuation of deferred tax assets.
Cash and Cash Equivalents	(E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had no
Concentration-Risk	(F) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed federally insured limits. As of March 31, 2022, the Company did have cash balances in excess of the federally insured limits. At March 31, 2021, the Company did not have any cash balances in excess of the federally insured limits.
Property & Equipment	(G) Property & Equipment Property and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after considering their respective estimated residual values) over the assets estimated useful life of ( 3 5 7
Patents and Trademarks	(H) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of useful life of 60
Loss Per Share	(I) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 3,754,484 1.20 6.67 4.95 The Company has 372,668 3.00 9.50 3.85 The Company has 195,000 1.39 1.99 1.56 The Company has 1,081,668 1.20 10.00 2.02 The Company uses the guidance in Accounting Standards Codification 260 (“ASC 260”) to determine if-converted loss per share. ASC 260 states that convertible securities should be considered exercised at the later date of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be anti-dilutive. At March 31, 2021, the Company had $ 230,000 5,671 June 30, 2021 230,000 5,671 81,579 2.89 196,000
Revenue Recognition	(J) Revenue Recognition The Company derives revenue from the sale of pet care products to its veterinarian customers in the Unites States. For performance obligations related to the sale of our pet care products, control transfers to the customer at a point in time. Revenue is recognized upon shipment, which is when control of these products is transferred to our customers and in an amount that reflects the consideration the Company expects to receive for these products. Shipping cost charged to customers are reported as an offset to the respective shipping cost. The Company does not have any significant financing components as payment is received at or shortly after the point of sale.
Accounts Receivable	(K) Accounts Receivable Accounts receivable are recorded at management’s assessment of the expected consideration to be received, based on a detailed review of historical pricing adjustments and collections. Management relies on the results of the assessment, which includes payment history of the applicable customer as a primary source of information in estimating the collectability of our accounts receivable. We update our assessment on a quarterly basis, which to date has not resulted in any material adjustments to the valuation of our accounts receivable. We believe the assessment provides reasonable estimates of our accounts receivable valuation, and therefore believe that substantially all accounts receivable are fully collectible.
Research and Development	(L) Research and Development The Company expenses research and development costs as incurred.
Fair Value of Financial Instruments	(M) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of accounts receivable, accounts payable, accrued expenses, accrued expenses – related parties, notes payable and accrued interest, and notes payable and accrued interest - related party, notes payable – directors and others. The carrying amount of the Company’s financial instruments approximates their fair value as of March 31, 2022 and 2021, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company had no
Stock-Based Compensation - Non-Employees	(N) Stock-Based Compensation - Non-Employees Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of Sub-topic 505-50 of the FASB Accounting Standards Codification (“Sub-topic 505-50”). Pursuant to ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. Pursuant to Paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a share option and similar instrument that the counterparty has the right to exercise expires unexercised.
Income Taxes	(O) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. As required by ASC Topic 450, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. At the adoption date, the Company applied ASC Topic 740 to all tax positions for which the statute of limitations remained open. As a result of the implementation of ASC Topic 740, the Company did not recognize any change in the liability for unrecognized tax benefits. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses.
Inventory	(P) Inventory Inventories are recorded in accordance with ASC 330, Inventory, and are stated at the lower of cost or net realizable value. We account for inventories using the first in first out (FIFO) methodology.
Recent Accounting Pronouncements	(Q) Recent Accounting Pronouncements The Company has reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) - Accounting for Convertible Instruments and Contracts on an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exceptions. The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early adoption is permitted. The Company is currently evaluating the impact of the adoption of the standard on the consolidated financial statements. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). The new ASU addresses issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact this new guidance will have on its financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.
Reclassifications	(R) Reclassifications Certain accounts in the prior year financial statements have been reclassified for comparative purposes to conform with the presentation in the current year financial statements. Accrued expenses is reported separately from accounts payable in the balance sheet since the amounts are material. In addition, the change in deferred offering costs is classified as a financing activity in the statement of cash flows. There was no effect on the change in net assets or net increase in cash and cash equivalents from these reclassifications.

INVENTORY (Tables)

INVENTORY (Tables)	12 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORY	The inventory components are as follows: SCHEDULE OF INVENTORY March 31, 2022 March 31, 2021 Finished Goods $ 11,889 $ 36,973 Work in Process 22,960 - Raw Materials 63,464 8,773 Manufacturing Supplies - 1,322 Inventory, Gross 98,313 47,068 Reserve for Obsolete Inventory - (47,068 ) Total Net $ 98,313 $ -

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	The components of property and equipment were as follows: SCHEDULE OF PROPERTY AND EQUIPMENT March 31, 2022 March 31, 2021 Leasehold improvements $ 216,159 $ 198,015 Production equipment 197,967 128,849 R&D equipment 25,184 25,184 Computer equipment and furniture 76,898 10,130 Total, at cost 516,208 362,178 Accumulated depreciation (204,659 ) (148,140 ) Total Net $ 311,549 $ 214,038

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF INTANGIBLE ASSETS	The components of intangible assets, all of which are finite-lived, were as follows: SCHEDULE OF INTANGIBLE ASSETS March 31, 2022 March 31, 2021 Patents $ 3,870,057 $ 3,840,903 Trademarks 26,142 26,142 Total at cost 3,896,199 3,867,045 Accumulated Amortization (3,847,747 ) (3,839,113 ) Total net $ 48,452 $ 27,932

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	12 Months Ended
	Mar. 31, 2022
Accrued Expenses
SCHEDULE OF COMPONENTS OF ACCRUED EXPENSES	The components of accrued expenses were as follows: SCHEDULE OF COMPONENTS OF ACCRUED EXPENSES March 31, 2022 March 31, 2021 Accrued payroll and related taxes $ 452,137 $ 221,774 Accrued lease termination expense 332,238 332,238 Total $ 784,375 $ 554,012

DERIVATIVE LIABILITY AND EXPE_2

DERIVATIVE LIABILITY AND EXPENSE (Tables)	12 Months Ended
	Mar. 31, 2022
Derivative Liability And Expense
SCHEDULE OF DERIVATIVE LIABILITY ASSUMPTIONS	The Company used the following assumptions for determining the fair value of the conversion feature in the RDCN referenced in Note 8 to these financial statements, under the binomial pricing model with Monte Carlo simulations at June 15, 2020, September 30, 2020 and October 26, 2020, the issuance, balance sheet, and conversion dates, respectively: SCHEDULE OF DERIVATIVE LIABILITY ASSUMPTIONS June 15, 2020 September 30, 2020 October 26, 2020 Stock price on valuation date $ 1.68 $ 1.60 $ 6.56 Conversion price $ 1.12 $ 1.12 $ 1.12 Days to maturity 273 166 140 Weighted-average volatility* 367 % 327 % 197 % Risk-free rate .18 % .12 % .11 %

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY	The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of March 31, 2022: SCHEDULE OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY 2023 $ 59,243 2024 60,588 2025 61,964 2026 63,372 2027 55,102 Total 300,270 Less: amount representing interest (1,169 ) Total $ 299,101
SCHEDULE OF BASE RENT LEASE PAYMENTS	SCHEDULE OF BASE RENT LEASE PAYMENTS Present value of future base rent lease payments $ 299,101 Present value of future base rent lease payments – net $ 299,101
SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES	As of March 31, 2022, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES Operating lease right-of-use asset $ 299,101 Total operating lease assets 299,101 Operating lease current liability 59,178 Operating lease other liability 239,923 Total operating lease liabilities $ 299,101

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	12 Months Ended
	Mar. 31, 2022
Equity [Abstract]
SCHEDULE OF TIME BASED RESTRICTED STOCK UNITS	Our time-based restricted stock unit activity for the year ended March 31, 2022 was as follows: SCHEDULE OF TIME BASED RESTRICTED STOCK UNITS Units Weighted Average Grant Date Fair Value Per Unit Aggregate Intrinsic Value (1) Balance at March 31, 2021 - - - Granted 549,565 $ 3.86 - Expired (4,073 ) $ 2.70 Vested (172,874 ) 3.44 Balance at March 31, 2022 372,668 $ 4.07 $ 760,243 (1) The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of this period.
SCHEDULE OF ESTIMATED FAIR VALUES ASSUMPTIONS	SCHEDULE OF ESTIMATED FAIR VALUES ASSUMPTIONS Year Ended March 31, 2022 Expected term 7 years Expected volatility 205.0% 210.5 % Risk-free interest rate 1.47% 2.14 % Expected dividend yield 0 % Fair value on the date of grant $ 1.39 1.99
SCHEDULE OF STOCK OPTION ACTIVITY	SCHEDULE OF STOCK OPTION ACTIVITY Options Weighted- Average Exercise Price Per Share (1) Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value (2) Balance at March 31, 2021 - - - - Granted 195,000 $ 1.56 - Balance at March 31, 2022 195,000 $ 1.56 6.9 $ 100,200 (1) The exercise price of each option granted during the period shown above was equal to the market price of the underlying stock on the date of grant. (2) The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of this period.
SCHEDULE OF ADDITIONAL INFORMATION ABOUT STOCK OPTIONS	The following summarizes additional information about our stock options: SCHEDULE OF ADDITIONAL INFORMATION ABOUT STOCK OPTIONS Year Ended March 31, 2022 Number of: Non-vested options, beginning of year - Non -vested options, end of year 195,000 Vested options, end of year - Year Ended March 31, 2022 Weighted-average grant date fair value of: Non-vested options, beginning of year - Non-vested options, end of year $ 1.56 Vested options, end of year - Forfeited options, during the year -
SCHEDULE OF WARRANT ACTIVITY	A summary of warrant activity for the year ending March 31, 2020 and nine-month period ending December 31, 2021 is as follows: SCHEDULE OF WARRANT ACTIVITY Number of Weighted-Average Warrants Weighted- Outstanding, March 31, 2020 1,234,295 $ 2.12 1,027,092 $ 2.13 Issued in conjunction with convertible debt 158,036 1.40 Sold for Cash 10,000 4.00 Issued and granted 72,596 1.52 Exercised for cash (205,946 ) (2.21 ) Cashless warrant exercises (142,313 ) (1.64 ) Expired (45,000 ) (3.78 ) Outstanding, March 31, 2021 1,081,668 2.02 881,982 2.00 Issued and granted 3,043,556 5.63 Exercised for cash (6,094 ) (6.90 ) Cashless warrant exercises (237,724 ) (1.58 ) Expired (15,922 ) (5.27 ) Cancelled (108,000 ) (1.79 ) Outstanding, March 31, 2022 3,757,484 $ 4.95 3,693,734 $ 5.00
SCHEDULE OF RANGE OF WARRANT PRICES	At March 31, 2022, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: SCHEDULE OF RANGE OF WARRANT PRICES Warrants Outstanding Warrants Exercisable Range of Warrant Exercise Price Number of Warrants Weighted- Average Exercise Price Weighted-Average Remaining Contractual Life (Years) Number of Warrants Weighted- Average Exercise Price $ 1.20 2.00 418,237 $ 1.35 3.93 418,237 $ 1.35 2.01 4.00 207,938 2.48 2.34 134,813 2.59 4.01 6.67 3,131,309 5.60 4.26 3,131,309 5.60 Total 3,757,484 $ 4.95 4.12 3,693,734 $ 5.00

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
SCHEDULE OF DEFERRED TAX ASSETS	The following table presents the net deferred tax assets as of March 31, 2022 and 2021: SCHEDULE OF DEFERRED TAX ASSETS 2022 2021 Net operating loss carryforwards $ 5,091,000 $ 4,924,000 Stock compensation 512,000 307,000 Other 96,000 44,000 Total deferred tax assets 5,699,000 5,275,000 Valuation allowance (5,699,000 ) (5,275,000 ) Net deferred tax assets $ — $ —
SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION	Income tax expense (benefits) to the statutory rate of 21% for the years ended March 31, 2022 and 2021 is as follows: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION 2022 2021 Tax benefits at statutory rate 21.0 % 21.0 % State income tax benefit, net of federal 7.7 % 7.7 % Tax rate adjustment to deferred tax assets - 3.2 % Gross effective rate 28.7 % 31.9 % Valuation allowance (28.7 %) (31.9 %) Net effective rate - -

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details Narrative) - USD ($)		1 Months Ended		12 Months Ended
	Aug. 13, 2021	Apr. 30, 2021	Oct. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 29, 2020	Oct. 26, 2020	Sep. 30, 2020	Jun. 15, 2020
Property, Plant and Equipment [Line Items]
Reverse stock split, description			the Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was effectuated on December 29, 2020; concurrently, the Company increased its authorized shares of common stock from 225,000,000 to 250,000,000; all share and per share data has been retroactively adjusted for this reverse split for all periods presented	1-for-4 reverse stock split
Common stock, shares authorized				250,000,000	250,000,000	225,000,000
Cash Equivalents, at Carrying Value					$ 0
Convertible notes interest		$ 2,658
Debt instrument maturity date				Apr. 30, 2020
Conversion of debt into common stock shares	43,556	80,522
Conversion price per share		$ 2.89					$ 1.12	$ 1.12	$ 1.12
Fair value, net asset (liability)				$ 0	0
Convertible Notes [Member]
Property, Plant and Equipment [Line Items]
Convertible notes outstanding					230,000
Convertible notes interest					$ 5,671
Debt instrument maturity date					Jun. 30, 2021
Conversion of debt into common stock shares					81,579
Conversion price per share					$ 2.89
Share-settled debt obligation with a related party					$ 196,000
Minimum [Member]
Property, Plant and Equipment [Line Items]
Weighted average, exercise price				$ 1.39
Maximum [Member]
Property, Plant and Equipment [Line Items]
Weighted average, exercise price				$ 1.99
Warrants [Member]
Property, Plant and Equipment [Line Items]
Warrants outstanding				3,754,484	1,081,668
Weighted average, exercise price				$ 4.95	$ 2.02
Warrants [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Warrant exercise price				1.20	1.20
Warrants [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Warrant exercise price				$ 6.67	$ 10
Restricted Stock Units [Member]
Property, Plant and Equipment [Line Items]
Warrants outstanding				372,668
Weighted average, exercise price				$ 3.85
Restricted Stock Units [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Warrant exercise price				3
Restricted Stock Units [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Warrant exercise price				$ 9.50
Options [Member]
Property, Plant and Equipment [Line Items]
Warrants outstanding				195,000
Weighted average, exercise price				$ 1.56
Options [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Warrant exercise price				1.39
Options [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Warrant exercise price				$ 1.99
Patents and Trademarks [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of intangible asset				60 months
Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of assets				3 years
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of assets				5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of assets				7 years

SCHEDULE OF INVENTORY (Details)

SCHEDULE OF INVENTORY (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021
Inventory Disclosure [Abstract]
Finished Goods	$ 11,889	$ 36,973
Work in Process	22,960
Raw Materials	63,464	8,773
Manufacturing Supplies		1,322
Inventory, Gross	98,313	47,068
Reserve for Obsolete Inventory		(47,068)
Total Net	$ 98,313

INVENTORY (Details Narrative)

INVENTORY (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventory, gross	$ 98,313	$ 47,068
Inventory reserves		47,068
Inventory written off	$ 47,068
Income recognized, change in reserve of obsolete inventory		$ 3,289

PREPAID EXPENSES AND DEFERRED_2

PREPAID EXPENSES AND DEFERRED OFFERING COSTS (Details Narrative) - USD ($)	Mar. 31, 2022	Mar. 31, 2021
Prepaid expenses and other assets	$ 547,664	$ 123,575
Deferred offering costs		280,163
Investor Relations Services [Member]
Prepaid expenses and other assets	220,000
Insurance Costs [Member]
Prepaid expenses and other assets	148,000	9,000
Clinical studies [Member]
Prepaid expenses and other assets	71,000
Trade shows [Member]
Prepaid expenses and other assets	46,000
Nasdaq fees [Member]
Prepaid expenses and other assets	$ 45,000
Advertising and Marketing Services [Member]
Prepaid expenses and other assets		78,000
OTC Registration Fee [Member]
Prepaid expenses and other assets		$ 9,000

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Line Items]
Total, at cost	$ 516,208	$ 362,178
Accumulated depreciation	(204,659)	(148,140)
Total Net	311,549	214,038
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	216,159	198,015
Equipment [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	197,967	128,849
R&D equipment [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	25,184	25,184
Computer equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	$ 76,898	$ 10,130

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 56,519	$ 36,554

SCHEDULE OF INTANGIBLE ASSETS (

SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 3,870,057	$ 3,840,903
Trademarks	26,142	26,142
Total at cost	3,896,199	3,867,045
Accumulated Amortization	(3,847,747)	(3,839,113)
Total net	$ 48,452	$ 27,932

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 8,634	$ 50,158

SCHEDULE OF COMPONENTS OF ACCRU

SCHEDULE OF COMPONENTS OF ACCRUED EXPENSES (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021
Accrued Expenses
Accrued payroll and related taxes	$ 452,137	$ 221,774
Accrued lease termination expense	332,238	332,238
Total	$ 784,375	$ 554,012

ACCRUED EXPENSES (Details Narra

ACCRUED EXPENSES (Details Narrative) - USD ($)	Mar. 31, 2022	Mar. 31, 2021	Jan. 31, 2020
Accrued Expenses
Accrued expense	$ 332,000	$ 332,000	$ 7,500

RELATED PARTY NOTES PAYABLE (De

RELATED PARTY NOTES PAYABLE (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2022	Dec. 31, 2021
Notes payable and accrued interest	$ 44,554
Debt instrument maturity date		Apr. 30, 2020
Annual monthly payments		$ 3,100
Debt term		24 months
Four Directors [Member]
Notes payable and accrued interest	$ 20,000		$ 0
Debt interest rate	6%
Minimum [Member]
Proceeds from related party debt		$ 3,500,000

NOTES PAYABLE AND CONVERTIBLE_2

NOTES PAYABLE AND CONVERTIBLE NOTES (Details Narrative) - USD ($)						1 Months Ended			6 Months Ended	12 Months Ended
	Aug. 13, 2021	Oct. 26, 2020	Oct. 26, 2020	Jun. 15, 2020	May 01, 2020	Jun. 30, 2021	Apr. 30, 2021	Oct. 31, 2020	Sep. 30, 2020	Mar. 31, 2022	Mar. 31, 2021	Aug. 31, 2021	Dec. 31, 2020	Jan. 31, 2020
Short-Term Debt [Line Items]
Notes payable														$ 42,500
Debt instrument, interest rate														6%
Convertible notes payable										$ 33,750	$ 39,528
Notes payable, current liabilities										6,549	39,528
Note payable other liabilities										$ 27,201
Convertible notes maturity date										Apr. 30, 2020
Debt instrument, periodic monthly payment										$ 3,100
Convertible notes payable											235,671
Accrued interest							$ 2,658
Debt conversion, shares issued	43,556						80,522
Conversion price per share		$ 1.12	$ 1.12	$ 1.12			$ 2.89		$ 1.12
Number of warrants purchase	43,556
Discount on debt				$ 206,000
Stock price												$ 4.50
Debt conversion stock valued										232,658	1,804,592
Gain on debt extinguishment											$ 366,903
Warrant [Member]
Short-Term Debt [Line Items]
Number of warrants purchase							4,500
Red Diamond Partners, LLC [Member]
Short-Term Debt [Line Items]
Debt principal amount								$ 368,995
Accrued interest								$ 1,729,005
Conversion price per share		$ 1.40	$ 1.40
Debt principal and accrued interest		$ 368,995	$ 368,995
Shares of common stock issued			263,568					263,568
Gain on debt extinguishment			$ 366,903
Convertible Note Payable [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate											10%
Debt principal amount											$ 230,000
Convertible notes payable											235,671
Accrued interest, current											5,671
Interest expenses											173,174
Convertible Notes Payable [Member] | Derivative [Member]
Short-Term Debt [Line Items]
Discount on debt									$ 206,000
Convertible Notes Payable [Member] | Investor [Member]
Short-Term Debt [Line Items]
Discount on debt									$ 2,500
Convertible Notes Payable [Member] | Think Warrants [Member]
Short-Term Debt [Line Items]
Fair value of warrants													$ 31,500
Payment of convertible debt										61,500
Number of warrants issued									75,000
Convertible Notes Payable [Member] | Think Equity [Member]
Short-Term Debt [Line Items]
Fair value of warrants										$ 52,399
Convertible Notes Payable [Member] | Red Diamond Partners, LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate				12.50%
Debt principal amount				$ 352,941									352,941
Shares issued, price per share				$ 1.12
Unamortized debt discount				$ 52,941							0		$ 52,941
Original issue discount percentage				15%
Number of warrants purchase													139,286
Fair value of warrants													$ 91,500
Reduction discounts on debt									$ 0
Payment of convertible debt									30,000
Owed amount											0
Convertible Notes Payable [Member] | Red Diamond Partners, LLC [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Discount on debt									$ 91,500
Paycheck Protection Program [Member]
Short-Term Debt [Line Items]
Notes payable						$ 3,769					$ 39,020
Debt instrument, interest rate					1%
Debt principal amount					$ 38,665
Convertible notes maturity date					May 01, 2022
Forgiveness of debt						31,680
Debt instrument, periodic monthly payment						$ 738
Note Conversion Agreement [Member]
Short-Term Debt [Line Items]
Debt principal amount		352,941	352,941
Accrued interest		$ 16,054	$ 16,054
Conversion price per share		$ 1.40	$ 1.40
Unamortized debt discount		$ 181,187	$ 181,187
Debt principal and accrued interest		$ 368,995	$ 368,995
Shares of common stock issued		263,568
Stock price		$ 6.56	$ 6.56
Derivative liability		$ 1,908,100	$ 1,908,100
Debt conversion stock valued		1,729,005
Gain on debt extinguishment		$ 366,903

SHARE-SETTLED DEBT OBLIGATION_2

SHARE-SETTLED DEBT OBLIGATION – RELATED PARTY (Details Narrative) - USD ($)			1 Months Ended	12 Months Ended
	Aug. 13, 2021	Sep. 02, 2020	Apr. 30, 2021	Mar. 31, 2022	Mar. 31, 2021	Oct. 15, 2020	Jan. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Accrued Interest			$ 2,658
Notes payable							$ 42,500
Debt interest rate							6%
Annual monthly payments				$ 3,100
Debt instrument maturity date				Apr. 30, 2020
Debt obligation converted	43,556		80,522
Common stock and warrants purchased	43,556
Warrants for purchase of common stock	43,556
Share-Settled Debt Obligations [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Notes payable					$ 196,000
Promissory Note [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt principal amount				$ 0	196,000
Related To Amendment Promissory Note [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt principal amount				$ 0	$ 44,554
David B Masters [Member] | Amended Promissory Note [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt principal amount		$ 59,642
Accrued Interest		6,058
Notes payable		$ 65,700
Debt interest rate		8%
Debt default interest rate		20%
Conditions of promissory notes, description		The Amendment to Promissory Note requires monthly payments of $3,100 and a maturity date of June 30, 2022, provided however that if the Company shall achieve $1,500,000 in equity sales or achieve gross product sales of $1,500,000, the Company must pay the outstanding balance at that time.
Annual monthly payments		$ 3,100
Debt instrument maturity date		Jun. 30, 2022
David B Masters [Member] | Promissory Note [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt principal amount		$ 195,000				$ 192,500
Accrued Interest						658
Notes payable						193,158
Conditions of promissory notes, description		David Masters’ release of any claim to the $195,000 in past accrued salary he was owed, it accrues interest at a rate of 3% per annum, has a maturity date of August 31, 2022, and required payments of $4,000 per month beginning when the Company’s sale of products reach $3,500,000. The reclassification of the $195,000 was treated as a debt modification.
Annual monthly payments		$ 4,000
Debt modification		$ 195,000
David B Masters [Member] | Promissory Note [Member] | Conversion Agreement [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt principal amount						192,500
Accrued Interest						658
Unamortized discount on debt						3,500
Conversion fee						$ 3,500

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITY ASSUMPTIONS (Details)	Oct. 26, 2020 $ / shares	Sep. 30, 2020 $ / shares	Jun. 15, 2020 $ / shares	Apr. 30, 2021 $ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock price on valuation date	$ 6.56	$ 1.60	$ 1.68
Conversion price	$ 1.12	$ 1.12	$ 1.12	$ 2.89
Days to maturity	140 days	166 days	273 days
Measurement Input, Option Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input, percentage	197	327	367
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement input, percentage	0.11	0.12	0.18

DERIVATIVE LIABILITY AND EXPE_3

DERIVATIVE LIABILITY AND EXPENSE (Details Narrative) - USD ($)			1 Months Ended		12 Months Ended
	Oct. 26, 2020	Jun. 15, 2020	Oct. 31, 2020	Sep. 30, 2020	Mar. 31, 2022	Mar. 31, 2021	Apr. 30, 2021
Corresponding offset to derivative liability		$ 526,800
Discount on debt		206,000
Convertible note embedded derivative liability		0
Derivative expense		320,800		$ 937,500		$ 1,702,100
Recognition of derivative liability		$ 526,800				1,702,100
Derivative liability	$ 1,908,100					0
Conversion price per share	$ 1.12	$ 1.12		$ 1.12			$ 2.89
Gain on debt extinguishment						$ 366,903
Red Diamond Partners, LLC [Member]
Shares of common stock issued	263,568		263,568
Conversion price per share	$ 1.40
Gain on debt extinguishment	$ 366,903

ACCRUED EXPENSES _ RELATED PA_2

ACCRUED EXPENSES – RELATED PARTY (Details Narrative) - USD ($)	1 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Accounts payable	$ 323,384	$ 408,873
Accrued salaries and payroll taxes payable	452,137	221,774
Proceeds from issuance initial public offering	$ 0
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued expenses, related party		36,808
Accounts payable		28,965
Accrued salaries and payroll taxes payable		$ 7,843

RETIREMENT PLAN (Details Narrat

RETIREMENT PLAN (Details Narrative)	12 Months Ended
	Mar. 31, 2022 USD ($)
Retirement Benefits [Abstract]
Discretionary contributions	$ 8,000

SCHEDULE OF ANNUAL UNDISCOUNTED

SCHEDULE OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY (Details)	Mar. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2023	$ 59,243
2024	60,588
2025	61,964
2026	63,372
2027	55,102
Total	300,270
Less: amount representing interest	(1,169)
Total	$ 299,101

SCHEDULE OF BASE RENT LEASE PAY

SCHEDULE OF BASE RENT LEASE PAYMENTS (Details)	Mar. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Present value of future base rent lease payments	$ 299,101
Present value of future base rent lease payments – net	$ 299,101

SCHEDULE OF LEASE CURRENT AND N

SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating lease right-of-use asset	$ 299,101
Total operating lease assets	299,101	$ 157,760
Operating lease current liability	59,178	26,582
Operating lease other liability	239,923	$ 131,178
Total operating lease liabilities	$ 299,101

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)	1 Months Ended		12 Months Ended
	Jan. 31, 2022 USD ($) ft²	May 31, 2017 ft²	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Jan. 31, 2020 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Area of land | ft²	2,400	3,577
Annual increase in base rent, percentage	0.025	0.02
Lease term description		In January 2020, the Company entered into a lease amendment whereby agreed to extend the lease term through November of 2026	the extended lease term to November 2026 and March 2027
Notes Payable					$ 42,500
Accrued expenses			$ 332,000	$ 332,000	$ 7,500
Base rent	$ 2,673		2,205
Lease rent expenses			81,816	56,546
Increase to operating lease right of use asset and operating lease liability			167,924
Operating lease right-of-use			$ 299,101	$ 157,760
Weighted average remaining lease term			4 years 9 months 18 days
Weighted average discount rate			0.28%
Payments to purchase inventory			$ 250,000
Extended Lease Term To 2026 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Operating lease right-of-use			$ 488,701
November 2026 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Operating lease treasury rate			0.12%
March 2026 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Operating lease treasury rate			0.40%

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	1 Months Ended
	Aug. 31, 2021	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from sale of stock	$ 9,781,000
Number of stock, sold during period	2,500,000
Sale of stock, price per share	$ 4.50
Working capital		$ 5,581,914

SCHEDULE OF TIME BASED RESTRICT

SCHEDULE OF TIME BASED RESTRICTED STOCK UNITS (Details)	12 Months Ended
	Mar. 31, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Time based RSU's, Weighted Average Grant Date Fair Value Per Unit, Granted | $ / shares	$ 1.56	[1]
Aggregate Intrinsic Value, RSU's, Balance
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Time based RSU's, Balance
Time based RSU's, Weighted Average Grant Date Fair Value Per Unit | $ / shares
Aggregate Intrinsic Value, RSU's, Balance		[2]
Time based RSU's Granted	549,565
Time based RSU's, Weighted Average Grant Date Fair Value Per Unit, Granted | $ / shares	$ 3.86
Aggregate Intrinsic Value, RSU's, Granted | $ / shares		[2]
Time based RSU's Expired	(4,073)
Time based RSU's, Weighted Average Grant Date Fair Value Per Unit, Expired | $ / shares	$ 2.70
Time based RSU's Vested	(172,874)
Time based RSU's, Weighted Average Vested Date Fair Value Per Unit, Vested | $ / shares	$ 3.44
Time based RSU's, Balance	372,668
Time based RSU's, Weighted Average Grant Date Fair Value Per Unit | $ / shares	$ 4.07
Aggregate Intrinsic Value, RSU's, Balance	760,243	[2]
[1] The exercise price of each option granted during the period shown above was equal to the market price of the underlying stock on the date of grant.

SCHEDULE OF ESTIMATED FAIR VALU

SCHEDULE OF ESTIMATED FAIR VALUES ASSUMPTIONS (Details)	12 Months Ended
	Mar. 31, 2022 $ / shares
Expected term	7 years
Expected volatility, minimum	205%
Expected volatility, maximum	210.50%
Risk-free interest rate, mimimum	1.47%
Risk-free interest rate, maximum	2.14%
Expected dividend yield	0%
Minimum [Member]
Fair value on the date of grant	$ 1.39
Maximum [Member]
Fair value on the date of grant	$ 1.99

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details)	12 Months Ended
	Mar. 31, 2022 USD ($) $ / shares shares
Equity [Abstract]
Options Outstanding, Beginning | shares
Weighted Average Exercise Price Per Share, Beginning | $ / shares		[1]
Aggregate Intrinsic Value, Beginning | $		[2]
Options Outstanding, Granted | shares	195,000
Weighted Average Exercise Price Per Share, Granted | $ / shares	$ 1.56	[1]
Options Outstanding, Ending | shares	195,000
Weighted Average Exercise Price Per Share, Ending | $ / shares	$ 1.56	[1]
Weighted Average Remaining Contractual Life	6 years 10 months 24 days
Aggregate Intrinsic Value, Ending | $	$ 100,200	[2]
[1] The exercise price of each option granted during the period shown above was equal to the market price of the underlying stock on the date of grant.

SCHEDULE OF ADDITIONAL INFORMAT

SCHEDULE OF ADDITIONAL INFORMATION ABOUT STOCK OPTIONS (Details)	12 Months Ended
	Mar. 31, 2022 $ / shares shares
Equity [Abstract]
Non-vested options, beginning of year | shares
Non -vested options, end of year | shares	195,000
Vested options, end of year | shares
Weighted-average grant date fair value, non-vested options, beginning of year
Weighted-average grant date fair value, non-vested options, end of year	1.56
Weighted-average grant date fair value, vested options, end of year
Weighted-average grant date fair value, forfeited options, during the year

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding, Balance	1,081,668	1,234,295
Weighted-Average Exercise Price, Outstanding, Balance	$ 2.02	$ 2.12
Warrants Exercisable, Outstanding, Balance	881,982	1,027,092
Weighted-Average Exercisable Price, Outstanding, Balance	$ 2	$ 2.13
Number of Warrants, Issued in conjunction with convertible debt		158,036
Weighted-Average Exercise Price, Issued in conjunction with convertible debt		$ 1.40
Number of Warrants, Sold for cash		10,000
Weighted-Average Exercise Price, Sold for cash		$ 4
Number of Warrants, Issued and granted	3,043,556	72,596
Weighted-Average Exercise Price, Issued and granted	$ 5.63	$ 1.52
Number of Warrants, Exercised for cash	(6,094)	(205,946)
Weighted-Average Exercise Price, Exercised for cash	$ (6.90)	$ (2.21)
Number of Warrants, Cashless warrant exercises	(237,724)	(142,313)
Weighted-Average Exercise Price, Cashless warrant exercises	$ (1.58)	$ (1.64)
Number of Warrants, Expired	(15,922)	(45,000)
Weighted-Average Exercise Price, Expired	$ (5.27)	$ (3.78)
Number of Warrants, Cancelled	(108,000)
Weighted-Average Exercise Price, Cancelled	$ (1.79)
Number of Warrants, Outstanding, Balance	3,757,484	1,081,668
Weighted-Average Exercise Price, Outstanding, Balance	$ 4.95	$ 2.02
Number of Warrants, Exercisable	3,693,734	881,982
Weighted-Average Exercise Price, Exercisable	$ 5	$ 2

SCHEDULE OF RANGE OF WARRANT PR

SCHEDULE OF RANGE OF WARRANT PRICES (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Mar. 31, 2022	Apr. 30, 2021	Mar. 31, 2021	Mar. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price		$ 4.44
Number of Warrants, Outstanding	3,757,484
Weighted-Average Exercise Price, outstanding	$ 4.95		$ 2.02	$ 2.12
Weighted-Average Remaining Contractual Life (Years), Outstanding	4 years 1 month 13 days
Number of Warrants, Exercisable	3,693,734		881,982	1,027,092
Weighted-Average Exercise Price, Exercisable	$ 5		$ 2	$ 2.13
Range One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding	418,237
Weighted-Average Exercise Price, outstanding	$ 1.35
Weighted-Average Remaining Contractual Life (Years), Outstanding	3 years 11 months 4 days
Number of Warrants, Exercisable	418,237
Weighted-Average Exercise Price, Exercisable	$ 1.35
Range Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding	207,938
Weighted-Average Exercise Price, outstanding	$ 2.48
Weighted-Average Remaining Contractual Life (Years), Outstanding	2 years 4 months 2 days
Number of Warrants, Exercisable	134,813
Weighted-Average Exercise Price, Exercisable	$ 2.59
Range Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding	3,131,309
Weighted-Average Exercise Price, outstanding	$ 5.60
Weighted-Average Remaining Contractual Life (Years), Outstanding	4 years 3 months 3 days
Number of Warrants, Exercisable	3,131,309
Weighted-Average Exercise Price, Exercisable	$ 5.60
Minimum [Member] | Range One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	1.20
Minimum [Member] | Range Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	2.01
Minimum [Member] | Range Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	4.01
Maximum [Member] | Range One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	2
Maximum [Member] | Range Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	4
Maximum [Member] | Range Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	$ 6.67

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative)									1 Months Ended															2 Months Ended		3 Months Ended		12 Months Ended
		Aug. 13, 2021 USD ($) $ / shares shares	Oct. 26, 2020 $ / shares shares	Sep. 14, 2020 USD ($) shares	Aug. 14, 2020 USD ($) $ / shares shares	Jul. 24, 2020 USD ($) $ / shares shares	Jul. 10, 2020 shares	Jul. 01, 2020 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) $ / shares shares	Jan. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Oct. 31, 2021 USD ($) shares	Sep. 30, 2021 USD ($) $ / shares shares	Aug. 31, 2021 USD ($) $ / shares shares	Jul. 31, 2021 USD ($) $ / shares shares	Jun. 30, 2021 $ / shares shares	May 31, 2021 $ / shares shares	Apr. 30, 2021 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) $ / shares shares	Feb. 28, 2021 $ / shares shares	Jan. 31, 2021 USD ($) $ / shares shares	Oct. 31, 2020 USD ($) $ / shares shares	Oct. 31, 2019 shares	Jun. 30, 2021 USD ($) $ / shares shares	Sep. 30, 2020 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Mar. 31, 2020 USD ($) shares	Mar. 31, 2022 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) $ / shares shares	Sep. 01, 2020 USD ($) $ / shares shares	Jun. 15, 2020 $ / shares
Subsidiary, Sale of Stock [Line Items]
Number of stock, sold during period														2,500,000
Sale of stock price per share | $ / shares														$ 4.50
Conversion of debt into common stock shares		43,556																80,522
Conversion of notes | $																		$ 230,000
Conversion price per share | $ / shares			$ 1.12															$ 2.89							$ 1.12						$ 1.12
Proceeds from Issuance Initial Public Offering | $									$ 0
Number of warrants purchase		43,556
Accrued interest | $																		$ 2,658
Common stock sold | $																												$ 5,311,629	$ 316,500
Stock issued for services | $																												524,230	541,208
Stock-based Compensation | $																												702,896	452,674
Proceeds from sale of stock | $														$ 9,781,000
Accrued expenses - related party | $									$ 784,375										$ 554,012									784,375	554,012
Restricted Stock or Unit Expense | $																												$ 606,014
Unrecognized compensation expenses recognition period																												6 years 10 months 24 days
Stock options vesting period																												3 years
Stock options contractual term																												7 years
Stock-based compensation expense | $																												$ 3,595
Options vested
Stock options exercisable									0																			0
Stock-based Compensation | $																												$ 702,896	$ 452,674
Measurement Input, Price Volatility [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant measurement inputs									315																			315
Measurement Input, Price Volatility [Member] | Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant measurement inputs																			350										350
Measurement Input, Price Volatility [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant measurement inputs																			433										433
Measurement Input, Expected Term [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercise term									5 years																			5 years
Measurement Input, Expected Term [Member] | Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercise term																			3 years										3 years
Measurement Input, Expected Term [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercise term																			5 years										5 years
Measurement Input, Risk Free Interest Rate [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant measurement inputs									0.82																			0.82
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant measurement inputs																										0.29
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant measurement inputs																										1.16
Convertible Note [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion of debt into common stock shares																					17,379
Conversion of notes | $																					$ 50,000
Conversion price per share | $ / shares																					$ 2.89
Accrued interest | $																					$ 205
Equity Option [Member]
Subsidiary, Sale of Stock [Line Items]
Unrecognized compensation expenses | $									$ 299,000																			$ 299,000
Red Diamond Partners, LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion price per share | $ / shares			$ 1.40
Accrued interest | $																						$ 1,729,005
Debt principal amount | $																						$ 368,995
Shares of common stock issued			263,568																			263,568
One Share of Common Stock and 1/2 Warrant Share [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock, sold during period																											20,000
Proceeds from Issuance of Warrants | $																											$ 34,709
Warrant transaction cost | $																											17,291
Proceeds from sale of stock | $																											$ 52,000
Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock sold, shares									162,524	10,000	300
Unrecognized pre-tax compensation expenses | $									$ 1,505,000																			$ 1,505,000
Unrecognized compensation expenses recognition period																												2 years 3 months 18 days
Options vested	[1]								760,243																			760,243
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock sold, shares																												3,189,248	1,070,424
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares																		$ 4.44
Number of warrants purchase																		4,500
Proceeds from warrant exercise | $																		$ 40,000
Unrecognized compensation expenses | $									$ 31,000																			$ 31,000
Number of Warrants, Granted																												3,043,556	72,596
Warrant [Member] | Think Equity [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares									$ 5.625																			$ 5.625
Common stock sold, shares																												500,000
Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Number of Warrants, Granted																													240,632
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares		$ 4.50
Conversion of debt into common stock shares														43,556
Conversion of notes | $														$ 196,000
Conversion price per share | $ / shares														$ 4.50
Proceeds from Issuance Initial Public Offering | $		$ 11,253,850
Underwriting Expense Ratio		8%
Equity public offerings | $		$ 1,473,067
Proceeds from issuance of common shares | $		4,891,531
Proceeds from Issuance of Warrants | $		$ 4,889,252
Common stock sold, shares		2,500,000
IPO [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Number of warrants purchase									3,043,556																			3,043,556
John Lai's [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares																	$ 1.33
Number of warrants purchase																	42,188
Common stock sold, shares																	36,915
Stock-based Compensation, shares				33,619
Warrant Holders [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares													$ 1.27	$ 1.40		$ 2.22	$ 1.40							$ 2.22
Number of warrants purchase														48,786		56,250	90,500							56,250
Common stock sold, shares													1,594	40,038		43,324	79,767
Proceeds from warrant exercise | $													$ 2,031
Accredited Investors [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares															$ 7	$ 7								$ 7
Common stock sold, shares															11,000									49,014
Common stock sold | $															$ 77,000									$ 343,098
Service Provider [Member]
Subsidiary, Sale of Stock [Line Items]
Stock issued for services, shares									8,609	7,500	500		42,000
Stock issued for services | $									$ 13,050	$ 20,100	$ 2,000		$ 210,000
Stock-based Compensation, shares																													30,000
Stock-based Compensation | $																													$ 32,453
Board of Director [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock sold, shares												25,585
Common stock sold | $												$ 69,080
Future Marketing and Investor Relations Services Provider [Member]
Subsidiary, Sale of Stock [Line Items]
Stock issued for services, shares									42,000
Stock issued for services | $									$ 210,000
Two Service Provider [Member]
Subsidiary, Sale of Stock [Line Items]
Stock issued for services, shares								12,500
Stock issued for services | $								$ 22,000
Marketing and Investor Relations Service Provider [Member]
Subsidiary, Sale of Stock [Line Items]
Stock issued for services, shares								10,000
Stock issued for services | $								$ 17,600
Legal Service Provider [Member]
Subsidiary, Sale of Stock [Line Items]
Stock issued for services, shares								2,500
Stock issued for services | $								$ 4,400
One Warrant Holder [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares						$ 1.20
Common stock sold, shares						15,257
Common stock sold | $						$ 12,053
Warrants converted on cashless basis						25,000
Four Accredited Investors [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock sold, shares																									226,071
Common stock sold | $																									$ 316,500
Directors and Officers [Member]
Subsidiary, Sale of Stock [Line Items]
Stock-based Compensation, shares				162,252
Stock-based Compensation | $				$ 486,755
John Carruth [Member]
Subsidiary, Sale of Stock [Line Items]
Stock-based Compensation, shares				26,217
John Dolan [Member]
Subsidiary, Sale of Stock [Line Items]
Stock-based Compensation, shares				22,993
Gregory Cash [Member]
Subsidiary, Sale of Stock [Line Items]
Stock-based Compensation, shares				10,789
David Deming [Member]
Subsidiary, Sale of Stock [Line Items]
Stock-based Compensation, shares				10,711
Robert Rudelius [Member]
Subsidiary, Sale of Stock [Line Items]
Stock-based Compensation, shares				10,627
Randy Meyer [Member]
Subsidiary, Sale of Stock [Line Items]
Stock-based Compensation, shares				10,550
Jim Martin [Member]
Subsidiary, Sale of Stock [Line Items]
Stock-based Compensation, shares				9,302
Scott Johnson [Member]
Subsidiary, Sale of Stock [Line Items]
Stock-based Compensation, shares				9,300
Joseph Jasper [Member]
Subsidiary, Sale of Stock [Line Items]
Stock-based Compensation, shares				9,209
David Masters [Member]
Subsidiary, Sale of Stock [Line Items]
Stock-based Compensation, shares				8,935
Three Directors [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion of notes | $					$ 25,383
Conversion price per share | $ / shares					$ 1.02
Accrued interest | $					$ 382
Number of shares issued for conversion					25,003
Outstanding balance | $					$ 25,382
Debt principal amount | $					$ 25,000
John Lais [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion price per share | $ / shares																					$ 1.33	$ 1.33
Common stock sold, shares																					42,188	42,188
Shares of common stock issued																					38,516	32,347
Escrowed shares																							150,000
Accrued expenses - related party | $									375,936																			$ 375,936
Accrued salary | $									$ 80,029																			80,029
Loss on extinguishment of debt | $																												$ 81,738
Twenty Accredited Investors [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion price per share | $ / shares																										$ 2.22
Proceeds from warrant exercise | $																										$ 449,993
Shares of common stock issued																										202,499
Warrant Holder [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion price per share | $ / shares																			$ 1.60	$ 4.44	$ 1.33								$ 1.60
Common stock sold, shares																				9,000	17,187
Proceeds from warrant exercise | $																			$ 5,504
Shares of common stock issued																			3,447	5,163	15,629
Investors [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares									$ 5.625																			$ 5.625
Common stock sold | $																												$ 4,805,528
Warrants to purchase common stock									2,500,000																			2,500,000
Director [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares									$ 5.625																			$ 5.625
Conversion of notes | $																												$ 196,000
Warrants to purchase common stock									43,556																			43,556
Conversion of Stock, Amount Issued | $																												$ 83,724
One Investor [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares																			$ 4										$ 4
Number of warrants purchase																			10,000										10,000
Warrants exercise term																			3 years										3 years
Warrant to purchase of common stock, value | $																			$ 17,291										$ 17,291
Directors Officers and Consultants [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares																			$ 1.52										$ 1.52
Number of warrants purchase																			38,846										38,846
Warrant to purchase of common stock, value | $								$ 6,600											$ 57,707										$ 57,707
Directors Officers and Consultants [Member] | Warrant [Member] | Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares																			$ 1.40										$ 1.40
Directors Officers and Consultants [Member] | Warrant [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares																			1.60										1.60
Investor and Broker [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares																			$ 1.40										$ 1.40
Number of warrants purchase																			158,036										158,036
Warrant to purchase of common stock, value | $																			$ 265,500										$ 265,500
Value of warrant vested | $																													$ 91,500
Two Directors [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares								$ 1.20
Number of warrants purchase								3,750
Warrants exercise term								5 years
Director Consulting Serives [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price | $ / shares																														$ 1.40
Number of warrants purchase																														30,000
Warrants exercise term																														5 years
Warrant to purchase of common stock, value | $																														$ 96,000
2020 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares of our common stock authorized							1,000,000
Expiration date							Jul. 10, 2030
Number of shares available to grant									233,923																			233,923
Common stock available and reserved to be issued							1,000,000
2020 Equity Incentive Plan [Member] | Non employee Director [Member]
Subsidiary, Sale of Stock [Line Items]
Maximum aggregate number of shares of common stock granted							25,000
Underwriting Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock, sold during period		2,500,000
Sale of stock price per share | $ / shares		$ 4.50
Warrant exercise price | $ / shares		$ 5.625
Conversion of debt into common stock shares		43,556
Conversion of notes | $		$ 196,000
Conversion price per share | $ / shares		$ 4.50
Underwriting agreement of shares, description																												In addition, pursuant to the Underwriting Agreement, the Company granted ThinkEquity a 45-day option to purchase up to 375,000 additional shares of common stock, and/or 375,000 additional warrants, to cover over-allotments in connection with the Offering, which ThinkEquity partially exercised to purchase 375,000 warrants on the closing date.
Number of warrants purchase		125,000
Sale of stock in puplic offering		0.05
Warrants exercise term		5 years
Warrant Holders [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion price per share | $ / shares																						$ 4.44
Common stock sold, shares																						6,750
Shares of common stock issued																						793
[1]The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of this period.

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 5,091,000	$ 4,924,000
Stock compensation	512,000	307,000
Other	96,000	44,000
Total deferred tax assets	5,699,000	5,275,000
Valuation allowance	(5,699,000)	(5,275,000)
Net deferred tax assets

SCHEDULE OF EFFECTIVE INCOME TA

SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Tax benefits at statutory rate	21%	21%
State income tax benefit, net of federal	7.70%	7.70%
Tax rate adjustment to deferred tax assets		3.20%
Gross effective rate	28.70%	31.90%
Valuation allowance	(28.70%)	(31.90%)
Net effective rate

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net operating loss carry forwards	$ 17,700,000	$ 17,100,000
Deferred tax assets	5,091,000	4,924,000
Change in the valuation allowance	$ 424,000	441,000
Net operating loss carry forwards, expiration period	The net operating loss carryforwards, if not utilized, generally expire twenty years from the date the loss was incurred, beginning in 2022, and losses incurred after 2019 are carried forward indefinitely and subject to annual limitations for federal and Minnesota purposes.
Accrued interest and penalties related to uncertain tax positions	$ 0	$ 0
Gel-Del Technologies, Inc [Member]
Net operating loss carry forwards	7,000,000
Accumulated pre-merger operating loss carryforwards	$ 7,000,000